Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection

Aktuelle Urologie

Volumn 34, Issue 4, 2003, Pages 256-258

  Okajima, E ^a   Uemura, H ^a   Ohnishi, S ^a   Tanaka, M ^a   Ohta, M ^a   Tani, M ^a   Fujimoto, K ^a   Ozono, S ^a   Hirao, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bladder neoplasm; Chemoprevention; Prostagalandin endoperoxide synthase; Recurrence

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; TUMOR MARKER;

ADULT; AGED; BLADDER CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER TISSUE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; TRANSURETHRAL RESECTION;

ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIROXICAM; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RISK FACTORS; SULFONAMIDES; URINARY BLADDER NEOPLASMS;

EID: 0042834157     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41610     Document Type: Conference Paper

References (21)

1. Lee C, Park MS. Prophylactic treatment of superficial bladder tumor. Int J Urol 1998; 5: 511-520
2. Droller MJ, Lindgren JA, Claessen HE, Perlmann P. Production of prostaglandin E2 by bladder tumor cells in tissue culture and a possible mechanism of lymphocyte inhibition. Cell Immunol 1979; 47: 261-273
3. Cohen SM, Zenser TV, Murasaki G, Fukushima S, Mattammal MB, Rapp NS, Davis BB. Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. Cancer Res 1981; 41: 3355-3359
4. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82: 1364-1369
5. Gwyn K, Sinicrope FA. Chemoprevention of colorectal cancer. Am J Gastroenterol 2002; 97: 13-21
6. Levi MS, Borne RF, Williamson JS. A review of cancer chemopreventive agents. Curr Med Chem 2001; 8: 1349-1362
7. Earnest DL, Hixson LJ, Alberts DS. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J Cell Biochem Suppl 1992; 161: 156-166
8. Kurata Y, Asamoto M, Hagiwara A, Masui T, Fukushima S. Promoting effects of various agents in rat urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Lett 1986; 32: 125-135
9. Sakata T, Hasegawa R, Johansson SL, Zenser TV, Cohen SM. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res 1986; 46: 3903-3906
10. Hasegawa R, St John M, Murasaki G, Fukushima S, Cohen SM. Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat. Cancer Lett 1984; 21: 269-275
11. Cohen SM, Hasegawa R, Sakata T, Johansson SL. Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats. Cancer Res 1989; 49: 372-377
12. Okajima E, Ozono S, Endo T, Majima T, Tsutsumi M, Fukuda T, Akai H, Denda A, Hirao Y, Okajima E, Nishino H, Nir Z, Konishi Y. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Jpn J Cancer Res 1997; 88: 543-552
13. Kennedy BP, Chan CC, Culp SA, Cromlish WA. Cloning and expression of rat prostagiandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem Biophys Res Commun 1993; 197: 494-500
14. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302: 723-727
15. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-9054
16. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-7388
17. Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, Kitayama W, Wakabayashi K, Konishi Y. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1998; 58: 3028-3031
18. Kitayama W, Denda A, Okajima E, Tsujiuchi T, Konishi Y. Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 1999; 20: 305-310
19. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647-5650
20. Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, Koch MO, Shappell SB, Breyer MD. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000; 157: 29-35
21. Ozono S, Hinotsu S, Tabata S, Takashima K, Fujimoto K, Okajima E, Hirao Y, Ohashi Y, Akaza H, Fukushima S. Treated natural history of superficial bladder cancer. Jpn J Clin Oncol 2001; 31: 536-540